Pharmaceutical News

RSS

Roche signs research collaboration and licensing agreement with Molecular Partners

Roche and Molecular Partners AG today announced that they have entered into a research collaboration and licensing agreement to discover, develop and commercialize several proprietary therapeutics incorporating Molecular Partners' DARPin biologics conjugated to toxic agents developed at Roche for the treatment of cancer.

4 Dec 2013

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

ARCA biopharma, Inc., a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that the Company's Gencaro Investigational New Drug application for atrial fibrillation has been accepted by the U.S. Food and Drug Administration and is now active.

4 Dec 2013

Japanese company places order for Nutranomics’ natural testosterone booster formula

Nutranomics, Inc.("Nutranomics" or the "Company") is pleased to report that it has received a purchase order for 500,000 capsules of a natural testosterone booster formula recently developed by Nutranomics.

4 Dec 2013

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Antiretroviral therapy for the treatment of HIV infection has saved 2.8 million years of life in South Africa since 2004 and is projected to save an additional 15.1 million years of life by 2030, according to a new study published online in The Journal of Infectious Diseases. The analysis suggests these dramatic benefits could be even greater if more aggressive HIV testing and treatment strategies are implemented.

4 Dec 2013

Researchers take important step towards development of future drugs for brain diseases

A successful joint collaboration between researchers at the Hebrew university of Jerusalem and the startup company TyrNovo may lead to a potential treatment of brain diseases. The researchers found that TyrNovo's novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan. This is a first and important step towards the development of future drugs for the treatment of various neurodegenerative maladies.

4 Dec 2013

Study compares efficacy and side effects of popular osteoporosis drugs

A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms.

4 Dec 2013

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva's innovative glatiramer acetate ( active ingredient) formulation for the treatment of multiple sclerosis, in Japan.

4 Dec 2013

New male contraceptive pill could soon be available

A new male contraceptive could be on the horizon after scientists identified a novel way to block the transport of sperm during ejaculation.

4 Dec 2013

People who rely on visual identification of medications may risk poor BP control

People who identify their blood pressure medications by shape, size and color instead of by name may risk poor blood pressure control and increase their risk of hospitalization, finds a recent study in the Journal of Health Communication: International Perspectives.

4 Dec 2013

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Cell Therapeutics, Inc. (CTI) announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for PIXUVRI® (pixantrone).

4 Dec 2013

Rensselaer professors team up to develop innovative biomanufacturing technology

Two chemical engineering professors at Rensselaer Polytechnic Institute are contributing to a collaboration among academia, industry, and the federal government to develop a method for rapidly manufacturing biologic drugs.

4 Dec 2013

MitoQ Targeted Antioxidant Dietary Supplement now available

MitoQ Limited is excited to announce the release of their newest offering, MitoQ Targeted Antioxidant Dietary Supplement. Published studies show that the supplement, which delivers the well known antioxidant CoQ to the mitochondria (our cellular power source) better than ever before, helps repair mitochondrial dysfunction, significantly reduces oxidative damage to cells and by association supports heart, liver and brain health while assisting in the increase of energy, libido and healthy aging.

3 Dec 2013

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

TxCell SA, a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen-specific regulatory T-cells (Ag-Tregs) for chronic inflammatory and autoimmune diseases, announces today that it received a Manufacturing Accreditation delivered by the French National Agency for Drug Safety. The status has been received for its cell therapy production site in Besançon, France.

3 Dec 2013

New catalog brings interactions between pharmacological molecules and proteins

The three-dimensional structures of proteins determine how, when and where they bind to drugs and other compounds. In 2012 alone, thousands of structures like this were resolved.

3 Dec 2013

Research proves effectiveness of vaccine against leishmaniasis

The disease is considered endemic in the south states of Mexico. A research executed in the Autonomous University of Yucatan (UADY) has successfully proved, in test animals, the effectiveness of a vaccine that immunizes the organism against leishmaniasis, an ailment transmitted through insects very similar to mosquitos and mainly presents symptoms in the skin, liver or spleen.

3 Dec 2013

Scientists investigate factors that influence choice of abused drugs

Prescription opioid abuse has reached epidemic levels in the past 15 years. Scientists investigating why people favor one drug over another have found that oxycodone and hydrocodone are the drugs of choice for 75% of opioid-dependent individuals.

3 Dec 2013

IRCM researcher sheds light on inconsistencies between pharmacogenomic studies

A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the prestigious scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

3 Dec 2013

ATN-224 inhibitor reduces tumor sizes in mouse model of lung adenocarcinoma

Many cancers have adapted to cope with high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1, is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy.

3 Dec 2013

Oxygen levels play critical role in determining effectiveness of anti-inflammatory drugs

A new research discovery published in the December 2013 issue of the Journal of Leukocyte Biology yields an important clue toward helping curb runaway inflammation. Oxygen levels play a critical role in determining the severity of the inflammatory response and ultimately the effectiveness of anti-inflammatory drugs.

3 Dec 2013

Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Pfizer Inc. today announced that a wholly-owned Polish subsidiary of Pfizer has acquired the rights to Polocard, a low-dose aspirin (acidum acetylsalicylicum), and the leading over-the-counter brand for heart attack prevention in Poland, from ZF Polpharma SA.

3 Dec 2013

Pharmaceutical News

Roche signs research collaboration and licensing agreement with Molecular Partners

FDA accepts ARCA biopharma's Gencaro IND application for atrial fibrillation

Japanese company places order for Nutranomics’ natural testosterone booster formula

Antiretroviral therapy for HIV treatment saves 2.8 million years of life in South Africa

Researchers take important step towards development of future drugs for brain diseases

Study compares efficacy and side effects of popular osteoporosis drugs

Takeda and Teva announce agreement related to commercialization of glatiramer acetate in Japan

New male contraceptive pill could soon be available

People who rely on visual identification of medications may risk poor BP control

Cell Therapeutics concludes agreement with GKV-SV regarding reimbursement price of PIXUVRI

Rensselaer professors team up to develop innovative biomanufacturing technology

MitoQ Targeted Antioxidant Dietary Supplement now available

TxCell receives Manufacturing Accreditation from ANSM for cell therapy production site in France

New catalog brings interactions between pharmacological molecules and proteins

Research proves effectiveness of vaccine against leishmaniasis

Scientists investigate factors that influence choice of abused drugs

IRCM researcher sheds light on inconsistencies between pharmacogenomic studies

ATN-224 inhibitor reduces tumor sizes in mouse model of lung adenocarcinoma

Oxygen levels play critical role in determining effectiveness of anti-inflammatory drugs

Pfizer's Polish subsidiary acquires rights to Polocard from ZF Polpharma SA

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News